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BACKGROUND AND PURPOSE
Intrathecally (i.t.) administered nociceptin/orphanin FQ (N/OFQ) evokes antinociceptive effects in rodents. Recent studies in
monkeys demonstrated that i.t. co-application of N/OFQ and morphine elicits synergistic antinociceptive actions suggesting
mixed N/OFQ peptide (NOP) and m opioid receptor agonists as innovative spinal analgesics. Thus, novel N/OFQ related
peptides were synthesized in order to identify and pharmacologically characterize a mixed NOP/ m opioid receptor agonist.
EXPERIMENTAL APPROACH
The following in vitro assays were used: calcium mobilization in cells expressing the human NOP or classical opioid receptors
and chimeric G proteins, receptor and [35S]-GTPgS binding, [35S]-GTPgS binding in rat spinal cord membranes, guinea pig
ileum bioassay. In vivo experiments were performed in monkeys using the tail withdrawal assay.
KEY RESULTS
From calcium mobilization studies [Dmt1]N/OFQ(1–13)-NH2 was selected as the most potent and least selective compound.
The mixed NOP/opioid full agonist activity and high affinity of [Dmt1]N/OFQ(1–13)-NH2 was confirmed at human
recombinant receptors in receptor binding, calcium mobilization and/or [35S]-GTPgS binding studies, at rat spinal cord
receptors in [35S]-GTPgS binding experiments, and at guinea pig receptors inhibiting neurogenic contractions in the ileum.
In vivo in the tail withdrawal assay in monkeys i.t. [Dmt1]N/OFQ(1–13)-NH2 was able to elicit robust and long-lasting
antinociceptive effects.
CONCLUSIONS AND IMPLICATIONS
Collectively, these results demonstrate that [Dmt1]N/OFQ(1–13)-NH2 behaves as NOP/opioid receptor universal agonist and
substantiate the suggestion that such mixed ligands are worthy of development as innovative spinal analgesics.
Abbreviations
N/OFQ, nociceptin/orphanin FQ; NOP receptor, N/OFQ peptide receptor
Introduction
The heptadecapeptide nociceptin/orphanin FQ (N/OFQ)
modulates various biological functions including locomotor
activity, anxiety and mood, memory, food intake, immunity,
heart rate and blood pressure, diuresis, gastrointestinal
motility, micturition and cough reflexes, and nociception
(Lambert, 2008) via selective activation of the N/OFQ peptide
BJP British Journal ofPharmacology
DOI:10.1111/j.1476-5381.2012.02115.x
www.brjpharmacol.org
British Journal of Pharmacology (2013) 168 151–162 151© 2012 The Authors
British Journal of Pharmacology © 2012 The British Pharmacological Society
(NOP) receptor (Meunier et al., 1995; Reinscheid et al., 1995).
In particular, pain transmission is modulated by N/OFQ in an
opposite manner depending on the site of administration. In
fact, rodent studies demonstrated that N/OFQ given supraspi-
nally produces pronociceptive effects and counteracts opioid-
induced analgesia while, when given spinally, the peptide
evokes, similar to opioids, antinociceptive effects (Zeilhofer
and Calo, 2003). The spinal antinociceptive action of N/OFQ
is dose-dependent, naloxone-insensitive, no longer evident
in mice knockout for the NOP receptor gene [NOP(–/–)],
mimicked by the NOP selective agonist UFP-112, and pre-
vented by selective NOP antagonists (UFP-101, SB-612111,
Compound 24) (Nazzaro et al., 2007; Rizzi et al., 2007a,b;
Fischetti et al., 2009). This effect of N/OFQ has been con-
firmed in non-human primates (Ko et al., 2006). The spinal
antinociceptive action of N/OFQ in monkeys is mimicked by
the intrathecal (i.t.) injection of the peptide UFP-112 (Hu
et al., 2009) as well as by the systemic administration of the
NOP selective non-peptide agonist Ro 64–6198 (Ko et al.,
2009). Moreover, the spinal antinociceptive effects of N/OFQ
and NOP agonists in monkeys are sensitive to the NOP selec-
tive antagonist J-113397 (Ko et al., 2006; 2009; Hu et al.,
2009). Interestingly, N/OFQ in combination with i.t. mor-
phine dose-dependently potentiated alkaloid-induced anal-
gesia in monkeys (Ko and Naughton, 2009). Thus, it seems
that the simultaneous activation of spinal NOP and opioid
(particularly the m opioid receptor) receptors is able to
produce a synergistic antinociceptive effect. Based on these
findings we may anticipate that molecules able to activate
with similar potencies NOP and opioid receptors (i.e. mixed
NOP/opioid agonists) represent an innovative and interesting
class of spinal analgesics.
Small molecules acting as mixed NOP/opioid agonists
have been previously described by industrial (Gruenenthal
and Purdue Pharma, see patent literature reviewed by Mus-
tazza and Bastanzio, 2011) and academic (Khroyan et al.,
2007; 2011; Spagnolo et al., 2008; Toll et al., 2009) laborato-
ries. The opposite action on nociception exerted by N/OFQ at
spinal versus supraspinal levels makes it difficult to predict
the analgesic potential of these compounds after systemic
administration; however, it is worth noting that several
mixed NOP/opioid receptor agonists have been demonstrated
to elicit robust antinociceptive effects in rodents after periph-
eral administration.
The aim of the present study was the design, synthesis
and pharmacological characterization of novel peptides
acting as non-selective NOP/opioid agonists and their in vivo
evaluation as spinal analgesics in monkeys. Thus, some [X1]
substituted N/OFQ analogues were synthesized and evaluated
pharmacologically in calcium mobilization experiments per-
formed in CHO cells expressing the human NOP or classical
opioid receptors as well as chimeric G-proteins that force
Gi-coupled receptors to signal via the PLC-IP3-Ca2+ pathway
(Camarda et al., 2009; Fischetti et al., 2009). From these
experiments, [Dmt1]N/OFQ(1–13)-NH2 was selected as the
most potent and least selective agonist. The pharmacological
profile of this peptide was then evaluated in vitro in (i) mem-
branes of CHO cells expressing the NOP, m, d or k opioid
receptor studied with receptor binding and stimulation of
[35S]-GTPgS binding experiments for m opioid and NOP recep-
tors; (ii) membranes of the rat cerebral cortex or spinal cord in
the [35S]-GTPgS assay; and (iii) the electrically stimulated
guinea pig ileum, a pharmacological preparation expressing
both m opioid and NOP receptors. The in vivo activity of
[Dmt1]N/OFQ(1–13)-NH2 was investigated by injecting the
peptide i.t. and measuring its effects in the tail withdrawal
assay in non-human primates.
Methods
Calcium mobilization
CHO cells stably co-expressing the human NOP, k or m opioid
receptor and the C-terminally modified Gaqi5 and CHO cells
expressing the d opioid receptor and the GaqG66Di5 protein were
maintained in culture medium consisting of Dulbecco’s
MEM/HAM’S F-12 (50/50) supplemented with 10% fetal calf
serum, penicillin (100 IU·mL-1), streptomycin (100 mg·mL-1),
fungizone (2.5 mg·mL-1), geneticin (G418; 200 mg·mL-1)
and hygromycin B (200 mg·mL-1) as described previously
(Camarda et al., 2009; Fischetti et al., 2009; Camarda and
Calo’, 2013). Cell cultures were kept at 37°C in 5% CO2
humidified air. In all cases, experimental cultures were free
from selection agents (hygromycin B, G418). When conflu-
ence was reached (3–4 days), cells were subcultured as
required using trypsin//EDTA and used for experimentation.
Cells were seeded at a density of 50 000 cells per well into
96-well black, clear-bottom plates. After 24 h incubation, the
cells were loaded with medium supplemented with 2.5 mM
probenecid, 3 mM of the calcium sensitive fluorescent dye
Fluo-4 AM and 0.01% pluronic acid, for 30 min at 37°C.
Afterwards, the loading solution was aspirated and 100 mL per
well of assay buffer: HBSS supplemented with 20 mM HEPES,
2.5 mM probenecid and 500 mM Brilliant Black (Sigma-
Aldrich, St. Louis, MO, USA) was added. Serial dilutions of
ligands for experimental use were made in HBSS/HEPES
(20 mM) buffer (containing 0.02% BSA fraction V). After
placing both plates (cell culture and compound plate) into the
FlexStation II (Molecular Device, Union City, CA, US), fluo-
rescence changes were measured at room temperature. Online
additions were carried out in a volume of 50 mL per well.
Receptor binding
These were performed using freshly prepared membranes
from CHO cells expressing human m, d, k opioid or NOP
receptors essentially according to McDonald et al. (2003).
Briefly, membranes (100 mg per tube) were incubated
in 0.5 mL volumes with a fixed concentration of
[3H]-diprenorphine ([3H]-DPN, 0.8 nM) for m, d and k opioid
receptors or [3H]-UFP-101 (1 nM) and increasing concentra-
tions of [Dmt1]N/OFQ(1–13)-NH2 and a range of reference
ligands as described in the Results section. Non-specific
binding was assessed using naloxone for m, d and k opioid
receptors for [3H]-DPN or J-113397 for [3H]-UFP-101. Bound
and free radioligand were separated following 1 h incubation
at room temperature by vacuum filtration.
[35S]-GTPgS stimulation binding
This was performed using freshly prepared membranes from
CHO cells expressing human m opioid or NOP receptors
(50 mg per tube) or frozen rat cerebral cortex or spinal cord
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membranes (100 mg per tube) essentially according to
McDonald et al. (2003). Briefly, membranes were incubated at
30°C in 0.5 mL of assay buffer supplemented with [35S]-GTPgS
(~160 pM) and increasing concentrations of [Dmt1]N/OFQ(1–
13)-NH2 and a range of reference ligands as described in the
Results section. Non-specific binding was defined in the pres-
ence of unlabelled GTPgS. Bound and free radioligand were
separated by vacuum filtration. Rats (Charles River Italia,
Lecco, Italy) were handled according to guidelines published
in the European Communities Council directives (86/609/
EEC) and National regulations (D.L. 116/92). They were
housed in 425 ¥ 266 ¥ 155 mm cages (Techniplast, Milsn,
Italy), eight per cage, under standard conditions (22°C, 55%
humidity, 12 h light/dark cycle, lights on at 07:00 h ) with
food (MIL, standard diet, Morini, Reggio Emilia, Italy) and
water ad libitum. The total number of rats used was 10. Rats
were killed by isofluorane overdose. These experiments and
protocols were approved by the University of Ferrara Ethic
Committee for Animal Research. All studies involving
animals are reported in accordance with the ARRIVE guide-
lines (Kilkenny et al., 2010; McGrath et al., 2010).
Electrically stimulated guinea pig ileum
Segments of ileum were taken from male albino guinea pigs
(300–350 g). The total number of guinea pigs used was 4. The
bioassay experiments were performed as previously described
(Bigoni et al., 1999). The tissues were suspended in 5 mL
organ baths containing Krebs solution (composition in mM:
NaCl 118.5, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25,
CaCl2 1.8, glucose 10, hexamethonium bromide 2.2 and
benadril 1.37) oxygenated with 95% O2 and 5% CO2. The
temperature was set at 37°C. A resting tension 1 g was applied
to the tissues. Tissues were stimulated through two platinum
ring electrodes with supramaximal rectangular pulses of 1 ms
duration and 0.05 Hz frequency. The electrically evoked con-
tractions were measured isotonically by means of Basile strain
gauge transducers and recorded with a personal computer-
based acquisition system (Power Lab, 4/25, ADInstruments,
Sydney, Australia). After an equilibration period of about
60 min, the contractions induced by electrical field stimula-
tion were stable. At this time, cumulative concentration–
response curves to agonists were performed (0.5 log unit
steps). Guinea pigs (Pampaloni, Siena, Italy) were handled
according to guidelines published in the European Commu-
nities Council directives (86/609/EEC) and National Regula-
tions (D.L. 116/92). They were housed in 425 ¥ 266 ¥ 155 mm
cages (Techniplast), five per cage, under standard conditions
(22°C, 55% humidity, 12 h light/dark cycle, light on at 07:00
h) with food (MIL, standard diet, Morini, Reggio Emilia) and
water ad libitum. Guinea pigs were killed by isofluorane over-
dose. These experiments and protocols were approved by the
University of Ferrara Ethic Committee for Animal Research.
Monkey tail withdrawal assay
Ten adult intact male and female rhesus monkeys (Macaca
mulatta) with body weights ranging between 6.8 and 12.5 kg
were used. The monkeys were housed individually with free
access to water and were fed approximately 25 biscuits
(Purina Monkey Chow; Ralston Purina, St. Louis, MO, USA)
and fresh fruit daily. No monkey had exposure to any opioid
drug 1 month before the present study. The monkeys were
housed in facilities accredited by the American Association
for the Accreditation of Laboratory Animal Care. The studies
were conducted in accordance with the University Commit-
tee on the Use and Care of Animals in the University of
Michigan (Ann Arbor, MI, USA) and the Guide for the Care
and Use of Laboratory Animals as adopted and promulgated
by the U.S. National Institutes of Health (Bethesda, MD,
USA).
The warm water tail-withdrawal assay was used to evalu-
ate thermal antinociceptive effects of the test compound (Ko
et al., 2006). Briefly, monkeys were seated in primate restraint
chairs, and the lower part of their shaved tails (approximately
15 cm) were immersed in a thermal flask containing water
maintained at either 42, 46 or 50°C. Tail-withdrawal latencies
were measured using a computerized timer by an experi-
menter who did not know dosing conditions. In each test
session, monkeys were evaluated once with three tempera-
tures given in a random order. If the monkeys did not remove
their tails within 20 s (cutoff), the flask was removed and a
maximum time of 20 s was recorded. Test sessions began with
determining a control value at each temperature. Subsequent
tail-withdrawal latencies were determined every 30 min after
i.t. administration. The same group of subjects (n = 4) was
tested in a 3 h time course by using a single dosing procedure.
Scratching behaviour, inferred as a response to itch sen-
sation (Ko et al., 2004), was recorded on videotape while the
monkeys were in their home cages. A scratch was defined as
one short-duration (<1 s) episode of scraping contact of the
forepaw or hind paw on the skin surface of other body parts.
Scratching responses were scored by individuals who were
blinded to experimental conditions. Each recording session
was conducted for 15 min per test session that occurred every
30 min after i.t. administration. The same group of subjects (n
= 6) was tested in a 3 h time course by using a single dosing
procedure.
For i.t. administration in monkeys, [Dmt1]N/OFQ(1–13)-
NH2 was administered at a total volume of 1 mL. The detailed
description for i.t. drug delivery can be referred to previous
studies (Ko et al., 2006). All experiments using i.t. adminis-
tration in monkeys were conducted with a 10-day inter-
injection interval.
Drugs
All peptides were prepared and purified as previously
described (Guerrini et al., 1997). All tissues culture media and
supplements were from Invitrogen (Paisley, UK). Peptides and
naloxone were solubilized in distilled water. J-113397 was
solubilized in DMSO at the concentration of 10 mM with
successive dilutions made in saline. Stock solutions were kept
at -20°C until use. For in vivo experiments peptides were
dissolved in sterile saline solution just before injections.
Data analysis and terminology
The drug and receptor nomenclature and terminology
adopted in this paper conforms to the guide to receptors and
channels (Alexander et al., 2011). All data are expressed as
means  SEM of n experiments. For potency values 95%
confidence limits were indicated.
Calcium mobilization data are expressed in fluorescence
intensity units (FIU) as % over the baseline. Receptor binding
BJP[Dmt
1]N/OFQ(1–13)-NH2 a universal opioid agonist
British Journal of Pharmacology (2013) 168 151–162 153
data are expressed as % displacement. [35S]-GTPgS data are
expressed as stimulation factor that is the ratio between spe-
cific agonist stimulated [35S]-GTPgS binding and basal specific
binding. Guinea-pig ileum data are expressed as % of the
control twitch induced by electrical field stimulation.
Affinity values are showed as pKi calculated using the
Cheng and Prusoff equation:
pK IC KDi log= + ( )[ ]{ }50 1 radiolabel
Agonist potencies are given as pEC50 = the negative logarithm
to base 10 of the molar concentration of an agonist that
produces 50% of the maximal possible effect. Concentration
response curve to agonists were fitted with the following
equation:
Effect baseline baseline
Hill Slope
= + +( )
+ −( ) ×
E
EC X
max
50^ log1 10 [ ]{ }
where X is the agonist concentration.
Antagonist potencies were derived from the Gaddum
Schild equation:
pK CRB antagonist= −( ) ( )[ ]log 1
Assuming a slope value equal to unity, where CR indicates the
ratio between agonist potency in the presence and absence of
antagonist.
For in vivo monkey studies, mean values (mean  SEM)
were calculated from individual values for all behavioural end
points. Comparisons were made for the same monkeys across
all test sessions. Data were analysed by a two-way repeated
ANOVA followed by the Newman–Keuls test for multiple
comparisons. The criterion for significant differences was set
at P < 0.05.
Results
In CHONOP cells stably expressing the Gaqi5 chimeric protein,
N/OFQ evoked a concentration-dependent stimulation of
calcium release displaying high potency [pEC50 9.30 (CL95%
9.05–9.55) ] and maximal effect (240  14% over the basal
values) while dermorphin was inactive up to 10 mM (Figure 1,
left panel). Opposite results were obtained in CHOMOP, CHO
cells stably expressing the Gaqi5 chimeric protein and human
m opioid receptors, where dermorphin concentration-
dependently stimulated calcium mobilization [pEC50 8.17
(CL95% 7.93–8.41) ]; Emax 130  12% over the basal values)
while N/OFQ was inactive up to 1 mM (Figure 1, right panel).
Under the same experimental conditions, N/OFQ analogues
were assayed in both cell lines. Table 1 summarizes the results
obtained in this series of experiments. The amide form of
N/OFQ displayed similar potency, maximal effects and selec-
tivity of action as the natural peptide. [Tyr1]N/OFQ-NH2 dis-
played a slight reduction in NOP potency [pEC50 9.14 (CL95%
8.93–9.35) ] while being able to activate the m opioid receptor,
although only in the micromolar range of concentrations
[pEC50 6.07 (CL95% 5.90–6.24) ]. The substitution of Phe1 with
Dmt produced a reduction of NOP potency by 10-fold [pEC50
8.57 (CL95% 8.28–8.86) ] associated with an important
increase in m opioid potency [pEC50 7.05 (CL95% 6.55–7.55) ].
Similar results were obtained when the [Tyr1] and [Dmt1]
modifications were applied to the N/OFQ(1–13)-NH2 tem-
plate. N/OFQ(1–13)-NH2 behaves as a highly potent [pEC50
9.49 (CL95% 9.42–9.56) ] and selective NOP agonist. [Tyr1]N/
OFQ(1–13)-NH2 displayed a slight reduction in NOP potency
[pEC50 9.16 (CL95% 8.91–9.41) ] and selectivity. [Dmt1]N/
OFQ(1–13)-NH2 similar to [Dmt1]N/OFQ-NH2 behaved as a
mixed NOP/m opioid receptor agonist showing only 26-fold
selectivity for NOP over m opioid receptors (Figure 1 and
Table 1). From this series of experiments, the compound
[Dmt1]N/OFQ(1–13)-NH2 was selected as the most potent and
least selective NOP/m opioid receptor agonist.
[Dmt1]N/OFQ(1–13)-NH2 affinity for NOP and classical
opioid receptors was assessed in displacement binding experi-
ments performed in membranes of CHO cells transfected
with human recombinant receptors and compared with
affinities of standard ligands. In CHONOP cell membranes,
N/OFQ displaced the radioligand with a pKi value of 10.18
(CL95% 10.01–10.35). N/OFQ(1–13)-NH2 bound the receptor
with a pKi of 10.60 (CL95% 10.41–10.79). The NOP selective
antagonist J-113397 displayed an affinity of 9.44 (CL95% 9.29–
Figure 1
Calcium mobilization experiments. Concentration–response curves to N/OFQ, dermorphin, and [Dmt1]N/OFQ(1–13)-NH2 in CHO cells stably
expressing the Gaqi5 chimeric protein and the NOP (left panel) and m opioid (right panel) human recombinant receptor. Data are the mean  SEM
of four separate experiments performed in duplicate.
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9.59). [Dmt1]N/OFQ(1–13)-NH2 displaced the radioligand
with a pKi value of 10.59 (CL95% 10.40–10.78) (Figure 2, left
top panel). In CHOMOP cell membranes, [Dmt1]N/OFQ(1–13)-
NH2 displaced [3H]-DPN with a pKi of 10.48 (CL95% 10.30–
10.66). The standard ligands dermorphin and naloxone
showed pKi values of 8.90 (CL95% 8.72–9.08) and 8.95 (CL95%
8.68–9.22), respectively (Figure 2, right top panel). In CHODOP
cell membranes, [Dmt1]N/OFQ(1–13)-NH2 showed a pKi value
of 9.43 (CL95% 9.27–9.59), where the standard d opioid recep-
tor agonist DPDPE, the selective d opioid receptor antagonist
naltrindole and the non-selective opioid receptor antagonist
naloxone displaced [3H]-DPN with pKi values of 7.29 (CL95%
7.09–7.49), 9.74 (CL95% 9.53–9.95) and 7.46 (CL95% 7.33–7.59),
respectively (Figure 2, left bottom panel). Finally, [Dmt1]N/
OFQ(1–13)-NH2 showed a pKi value of 9.83 (CL95% 9.45–
10.21) in CHOKOP cell membranes. The k opioid receptor
agonist dynorphin A displayed a pKi value of 10.71
(CL95% 10.14–11.28), where the k opioid receptor selective
Table 1
Effects of standard and novel agonists in calcium mobilization experiments performed in CHO cells stably expressing the human NOP or m opioid
receptor and the Gaqi5 protein
NOP m
m /NOPpEC50(CL95%) Emax  SEM pEC50(CL95%) Emax  SEM
Dermorphin <5 – 8.17 (7.93–8.41) 133  12% <0.0007
N/OFQ 9.30 (9.05–9.55) 235  14% <5 – >20.000
N/OFQ-NH2 9.49 (9.42–9.56) 255  13% <5 – >30.000
[Tyr1]N/OFQ-NH2 9.14 (8.93–9.35) 289  14% 6.07 (5.90–6.24) 121  16% 1174
[Dmt1]N/OFQ-NH2 8.57 (8.28–8.86) 259  7% 7.05 (6.55–7.55) 97  10% 33
N/OFQ(1–13)-NH2 9.49 (9.42–9.56) 222  10% <5 - >30.000
[Tyr1]N/OFQ(1–13)-NH2 9.16 (8.91–9.41) 235  17% 6.01 (5.67–6.49) 105  6% 1412
[Dmt1]N/OFQ(1–13)-NH2 8.94 (8.39–9.49) 242  12% 7.52 (7.18–7.86) 126  18% 26
The values are the means of three to four separate experiments performed in duplicate.
Figure 2
Receptor binding experiments. Competition binding curves to [Dmt1]N/OFQ(1–13)-NH2 and standard ligands in membranes of CHO cells
expressing NOP (top left panel), m (top right panel), d (bottom left panel) or k (bottom right panel) opioid receptors. [3H]-UFP-101 was used as
radioligand for the NOP and [3H]-DPN for classical opioid receptors. Data are the mean  SEM of 3 separate experiments performed in duplicate.
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antagonist nor-binaltorphimine and the opioid universal
ligand naloxone displaced [3H]-DPN with pKi values of 10.14
(CL95% 9.51–10.79) and 8.44 (CL95% 8.25–8.63), respectively
(Figure 2, right bottom panel). Thus, receptor binding experi-
ments not only confirmed that [Dmt1]N/OFQ(1–13)-NH2
binds with high affinity to NOP and m opioid receptor sites,
but also demonstrated that the peptide behaves as a potent k
and d opioid receptor ligand. On this basis, a separate series of
experiments were performed to investigate the pharmaco-
logical activity of [Dmt1]N/OFQ(1–13)-NH2 at k and d opioid
receptors.
In CHOKOP cells stably expressing the Gaqi5 chimeric
protein, dynorphin A evoked a concentration-dependent
stimulation of calcium release displaying high potency [pEC50
8.92 (CL95% 8.53–9.31) ] and maximal effect (230  15% over
the basal values) while N/OFQ was inactive up to 1 mM.
[Dmt1]N/OFQ(1–13)-NH2 mimicked the stimulating effects of
dynorphin A showing similar maximal effects, but 20-fold
lower potency [pEC50 7.61 (CL95% 7.31–7.91) ] (Figure 3, left
panel). In CHODOP cells stably expressing the GaqG66Di5 chi-
meric protein, DPDPE concentration-dependently stimulated
calcium mobilization { [pEC50 8.10 (CL95% 7.90–8.30) ]; Emax
121  14% over the basal values} while N/OFQ was inactive
up to 1 mM (Figure 3, right panel). [Dmt1]N/OFQ(1–13)-NH2
induced a concentration-dependent stimulation of calcium
release showing maximal effects similar to DPDPE, but lower
potency (pEC50 7.24 (CL95% 6.60–7.88)) (Figure 3, right panel).
In CHONOP cell membranes, N/OFQ stimulated [35S]-GTPgS
binding in a concentration-dependent manner with a pEC50
value of 8.52 (CL95% 7.92–9.12) and Emax of 4.80  0.37.
N/OFQ(1–13)-NH2 and [Dmt1]N/OFQ(1–13)-NH2 mimicked
the stimulating effect of the natural peptide showing similar
potency and maximal effects. The m opioid receptor agonist
dermorphin produced a weak stimulation only at the highest
concentration tested that is 10 mM (Figure 4, left panel). In
contrast, in CHOMOP cell membranes, dermorphin, stimulated
[35S]-GTPgS binding in a concentration-dependent manner
with high potency and maximal effects [pEC50 7.74 (CL95%
7.56–7.91); Emax of 5.47  0.13]. [Dmt1]N/OFQ(1–13)-NH2
mimicked the stimulant effect of the opioid peptide showing
similar maximal effects and even higher potency [pEC50 8.19
(CL95% 8.00–8.39) ]. In these cell membranes, N/OFQ was
found to be inactive up to mM concentrations (Figure 4, right
panel).
In rat cerebral cortex membranes (Figure 5), N/OFQ
stimulated [35S]GTPgS binding in a concentration-dependent
manner with a pEC50 value of 7.82 (CL95% 7.49–8.15) and Emax
of 1.40  0.03. N/OFQ(1–13)-NH2 mimicked the stimulatory
Figure 3
Calcium mobilization experiments. Concentration–response curves to N/OFQ, [Dmt1]N/OFQ(1–13)-NH2, and standard opioid agonists (dynor-
phin A and DPDPE for k and d opioid receptors, respectively) in CHO cells stably expressing chimeric G proteins and the k (left panel) and d (right
panel) human recombinant opioid receptor. Data are the mean  SEM of four separate experiments performed in duplicate.
Figure 4
[35S]-GTPgS binding experiments. Concentration–response curves to N/OFQ, N/OFQ(1–13)-NH2, dermorphin, and [Dmt1]N/OFQ(1–13)-NH2 in
membranes of CHO cells stably expressing the NOP (left panel) or m (right panel) human recombinant opioid receptors. Data are the mean  SEM
of five separate experiments performed in duplicate.
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effect of N/OFQ with similar maximal effects, but higher
potency [pEC50 8.48 (CL95% 8.09–8.87) ]. The MOP agonist
dermorphin displayed a relatively low potency in this prepa-
ration and this prevented a precise determination of its
maximal effects. [Dmt1]N/OFQ(1–13)-NH2 produced a stimu-
lation of [35S]GTPgS binding with a pEC50 value of 8.01 (CL95%
7.969–8.32) and Emax of 1.68  0.04; of note, the maximal
effect elicited by [Dmt1]N/OFQ(1–13)-NH2 was significantly
higher than those produced by the other ligands (Figure 5).
In rat spinal cord membranes N/OFQ and N/OFQ(1–13)-
NH2 produced superimposable results (pEC50 ª 7.6;
Emax ª 1.25). Dermorphin displayed a lower potency [pEC50 of
6.41 (CL95% 5.66–7.17) ] but higher maximal effect
(1.42  0.10). [Dmt1]N/OFQ(1–13)-NH2 produced a stimula-
tion of [35S]GTPgS binding with similar potency to N/OFQ
[pEC50 7.81 (CL95% 7.47–8.16) ] and maximal effects higher
than those elicited by dermorphin (Figure 6, top left panel).
In this preparation, the stimulatory effects of N/OFQ, der-
morphin and [Dmt1]N/OFQ(1–13)-NH2 were challenged with
the NOP selective antagonist J-113397 and the universal
opioid receptor antagonist naloxone. As shown in Figure 6
top right panel, the effects of N/OFQ were resistant to
naloxone while sensitive to J-113397 (pKB 7.95). In contrast,
the action of dermorphin was antagonized by naloxone (pKB
8.07), but not by J-113397 (bottom left panel). As shown in
Figure 6 bottom right panel, the stimulating effect elicited by
[Dmt1]N/OFQ(1–13)-NH2 was sensitive to both naloxone and
J-113397. Co-application of the two antagonists did not
produce a further shift in the concentration-response curve to
[Dmt1]N/OFQ(1–13)-NH2.
In the electrically stimulated guinea pig ileum, N/OFQ
inhibited the twitch response in a concentration-dependent
manner [pEC50 8.26 (CL95% 8.16–8.36), Emax = 40  2% inhi-
bition of control twitch]. The m opioid receptor agonist der-
morphin mimicked the effect of N/OFQ being, however,
more potent (pEC50 8.61 (CL95% 8.50–8.72) and efficacious
(Emax = 80  2% inhibition of control twitch). [Dmt1]N/
OFQ(1–13)-NH2 inhibited the electrically induced twitch
showing similar potency and maximal effects as dermorphin
(Figure 7, top left panel). The inhibitory action of N/OFQ was
not affected by naloxone, but was antagonized by J-113397
Figure 5
[35S]-GTPgS binding experiments. Concentration–response curves to
N/OFQ, N/OFQ(1–13)-NH2, dermorphin, and [Dmt1]N/OFQ(1–13)-
NH2 in membranes of the rat cerebral cortex. Data are the
mean  SEM of four separate experiments performed in duplicate.
Figure 6
[35S]-GTPgS binding experiments. Concentration–response curves to N/OFQ, N/OFQ(1–13)-NH2, dermorphin, and [Dmt1]N/OFQ(1–13)-NH2 in
membranes of the rat spinal cord (top left panel). Effects of naloxone and J-113397 versus N/OFQ (top right panel), dermorphin (bottom left
panel), and [Dmt1]N/OFQ(1–13)-NH2 (bottom right panel). Data are the mean  SEM of five separate experiments performed in duplicate.
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(pKB 7.87) (Figure 7, top right panel). In contrast, the effects
of dermorphin were sensitive to naloxone (pKB 8.55) but not
J-113397 (Figure 7, bottom left panel). Finally, the effects of
[Dmt1]N/OFQ(1–13)-NH2 were challenged with J-113397,
naloxone and the cocktail of the two antagonists. As shown
in Figure 7 bottom right panel, naloxone antagonized the
inhibitory effect of [Dmt1]N/OFQ(1–13)-NH2 producing a
rightward shift of the concentration-response curve and no
modifications of maximal effects; a pKB value of 7.97 was
derived from these experiments. J-113397 1 mM was also able
to counteract [Dmt1]N/OFQ(1–13)-NH2 effects by producing a
slight displacement to the right of the concentration–
response curve associated with a reduction in maximal effect;
a pKB value of 5.96 was derived from these experiments.
When the two antagonists were assayed together, they dis-
played an additive effect.
Finally, the in vivo effects of [Dmt1]N/OFQ(1–13)-NH2 on
pain transmission were evaluated in non-human primates
after spinal administration (Figure 8). In the dose range 1 and
10 nmol, the peptide produced dose-dependent antinocicep-
tive effects. Of note at 10 nmol [Dmt1]N/OFQ(1–13)-NH2 elic-
ited maximal antinociceptive effects (top left panel) without
causing itch/scratching responses (top right panel). By con-
trast, supramaximal doses of peptide, 30 and 100 nmol, still
produced full antinociceptive effects (bottom left panel) that
were, however, associated with robust scratching responses
(bottom right panel).
Discussion
Based on the recent evidence of a synergistic antinociceptive
effect in response to the simultaneous activation of spinal
NOP and opioid receptors (Hu et al., 2009; Ko and Naughton,
2009), the present study was carried out with the aim of
identifying, pharmacologically characterize and evaluate
mixed NOP/opioid agonists as innovative spinal analgesics.
[Dmt1]N/OFQ(1–13)-NH2 was identified in the calcium mobi-
lization primary screening assay as the most potent and least
selective agonist. The pharmacological activity of the peptide
was then confirmed in various in vitro assays performed on
recombinant human receptors (receptor binding, [35S]-GTPgS
binding) as well as at native animal receptors expressed in the
rat cerebral cortex and spinal cord and in the guinea pig
ileum. In vivo in the tail withdrawal assay performed in
monkeys [Dmt1]N/OFQ(1–13)-NH2 produced dose-dependent
antinociceptive effects. Of note, while [Dmt1]N/OFQ(1–13)-
NH2 displayed similar potency to N/OFQ in vitro, the peptide
was approximately 30-fold more potent in vivo and elicited
longer-lasting effects. These results corroborate the hypoth-
esis that non-selective NOP/opioid agonists may behave as
innovative spinal analgesics and [Dmt1]N/OFQ(1–13)-NH2 is
a prototype for this class of drugs.
The calcium mobilization assay used for screening the
NOP/opioid receptor ligands has been validated in previous
studies. In particular, the pharmacological profile of the
Figure 7
Electrically stimulated guinea-pig ileum. Concentration-response curves to N/OFQ, dermorphin, and [Dmt1]N/OFQ(1–13)-NH2 (top left panel).
Effects of naloxone and J-113397 vs N/OFQ (top right panel), dermorphin (bottom left panel), and [Dmt1]N/OFQ(1–13)-NH2 (bottom right
panel). Data are the mean  SEM of four separate experiments performed in duplicate.
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human NOP receptor coupled with calcium signalling has
been assessed with a rather large panel of ligands encompass-
ing full and partial agonist as well as pure antagonist activity
(Camarda et al., 2009). Similar experiments were performed
to investigate the pharmacological profile of human classical
opioid receptors although, in this case, the panel of ligands
investigated was relatively small (Camarda and Calo, 2013).
The results obtained with the calcium assay were virtually
identical to those described in the literature using classical
assays for Gi-coupled receptors (i.e. cAMP levels or stimula-
tion of [35S]-GTPgS binding in cells expressing recombinant
receptors, inhibition of electrically induced contractions in
isolated tissues). For instance, the correlation analysis of
results obtained with NOP ligands in the calcium mobiliza-
tion and in the mouse vas deferens assays yielded a correla-
tion coefficient r2 of 0.90 (Camarda et al., 2009).
The design of non-selective NOP/opioid agonists was
based on the following evidence: (i) N/OFQ(1–13)-NH2 main-
tains the same potency and efficacy as the natural peptide
(Calo et al., 1996; Guerrini et al., 1997); (ii) the substitution of
Phe1 with Tyr in N/OFQ as well as N/OFQ(1–13)-NH2
sequences causes a reduction in selectivity for NOP over clas-
sical opioid receptors (Calo et al., 1997; Varani et al., 1999);
and (iii) the substitution of Tyr1 with Dmt in opioid peptide
sequences increases ligand potency (Salvadori et al., 1995;
Schiller, 2010). The results obtained in the calcium assay
demonstrated that this design strategy was indeed successful.
In fact, the substitution of Phe with Tyr in position 1 gener-
ated less selective peptides. However, both [Tyr1]N/OFQ-NH2
and [Tyr1]N/OFQ(1–13)-NH2 were more than 1000-fold more
potent at NOP than at m opioid receptors. These results are in
line with previous findings. In fact, [Tyr1]N/OFQ-NH2 and
[Tyr1]N/OFQ(1–13)-NH2 were able to bind to both NOP and m
opioid receptor sites in guinea pig brain membranes but with
higher affinity at the former receptor (Varani et al., 1999).
Moreover, in the electrically stimulated guinea pig ileum
Figure 8
Monkey tail withdrawal assay. Effect of low (top panels) and high (bottom panels) doses of [Dmt1]N/OFQ(1–13)-NH2 on nociception (left panels)
and scratching behaviour (right panels). Data are the mean  SEM of data (four separate experiments for left panels and six experiments for right
panels). The asterisk represents a significant difference from the vehicle condition from the time point 30 min to the corresponding time point
for each dose (*P < 0.05).
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[Tyr1]N/OFQ(1–13)-NH2, at low concentrations (<30 nM),
produced naloxone-resistant inhibitory effects; however, at
higher concentrations, the opioid antagonist partially coun-
teracted the action of the peptide (Varani et al., 1999). Finally,
when tested in vivo, [Tyr1]N/OFQ mimicked the effect of the
natural peptide decreasing systemic arterial pressure in the rat
(Champion and Kadowitz, 1997) and eliciting erectile activity
in the cat (Champion et al., 1998). The non-natural amino
acid Dmt has been widely and successfully used in the past
for generating highly potent ligands for opioid receptors
(Bryant et al., 2003; Schiller, 2010) and also, opioid/
neurotensin hybrid peptides (Kleczkowska et al., 2010). The
ability of this residue to increase opioid receptor affinity com-
pared with Tyr has been confirmed in the present study. In
fact [Dmt1]N/OFQ-NH2 and [Dmt1]N/OFQ(1–13)-NH2 dis-
played a slight decrease in NOP potency associated with a
substantial increase in potency at m opioid receptors. As a
consequence, the selectivity of these peptides for NOP over m
opioid receptors dropped to only ª30-fold. Because [Dmt1]N/
OFQ(1–13)-NH2 displayed slightly higher potency and lower
selectivity compared with [Dmt1]N/OFQ-NH2, it was selected
as candidate for further studies.
Very high NOP/ m opioid receptor affinity of [Dmt1]N/
OFQ(1–13)-NH2 was demonstrated in receptor binding
experiments performed using membranes prepared from
CHO cells expressing NOP or classical opioid receptors. These
experiments also demonstrated that the peptide is capable of
binding to d and k opioid receptors, although with lower
affinity. Functional calcium mobilization studies indicated
that [Dmt1]N/OFQ(1–13)-NH2 behaves as a full agonist also at
d and k opioid receptors. [Dmt1]N/OFQ(1–13)-NH2 affinity in
receptor binding experiments matched its potency in calcium
mobilization studies and the same rank order that is NOP > m
 k > d has been determined for [Dmt1]N/OFQ(1–13)-NH2 in
the two sets of data. In [35S]-GTPgS assay, the peptide behaved
as potent full agonist both at NOP and at m opioid receptors.
In these experiments, [Dmt1]N/OFQ(1–13)-NH2 displayed, in
line with calcium mobilization data, higher potency at NOP
than at m opioid receptors, but its ratio of selectivity (2) was
substantially lower than that derived from calcium mobiliza-
tion studies. Collectively, these results clearly demonstrated
that [Dmt1]N/OFQ(1–13)-NH2 behaved as a universal NOP/
opioid full agonist at recombinant human receptors.
The pharmacological activity of the peptide was then
reassessed at native animal receptors by performing [35S]-
GTPgS binding experiments with membranes from the rat
cerebral cortex and spinal cord and bioassay experiments in
the guinea pig ileum. In line with previous findings, N/OFQ
and dermorphin stimulated [35S]-GTPgS binding in the rat
cerebral cortex and spinal cord membranes (Sim et al., 1995;
Albrecht et al., 1998; Narita et al., 1999a,b). In both prepara-
tions, [Dmt1]N/OFQ(1–13)-NH2 behaved as a potent agonist
producing maximal effects higher than those elicited by the
selective agonists. The receptor mechanism involved in the
stimulant effects of [Dmt1]N/OFQ(1–13)-NH2 in rat spinal
cord membranes has been investigated in receptor antagonist
experiments. While the stimulating effects of N/OFQ and
dermorphin were sensitive to J-113397 and naloxone, respec-
tively, that elicited by [Dmt1]N/OFQ(1–13)-NH2 was counter-
acted by both molecules. This result suggests that stimulation
of [35S]-GTPgS binding by N/OFQ and dermorphin derives
from the selective activation of NOP and opioid receptors,
respectively, while that elicited by [Dmt1]N/OFQ(1–13)-NH2 is
due to the simultaneous activation of both types of receptors.
This view is corroborated by findings obtained in the electri-
cally stimulated guinea pig ileum. In this preparation,
J-13397 and naloxone selectively antagonized the inhibitory
effects of N/OFQ and dermorphin, respectively, with pKB
values similar to those obtained in the rat spinal cord mem-
branes and the literature (Calo et al., 1997; Bigoni et al.,
2000). In contrast, the inhibitory action of [Dmt1]N/OFQ(1–
13)-NH2 was sensitive to both antagonists and a profound
shift to the right of the concentration–response curve to the
agonist was obtained when J-113397 and naloxone were
co-applied. Collectively, these findings clearly demonstrate
that [Dmt1]N/OFQ(1–13)-NH2 acts as a potent and mixed
NOP/opioid full agonist at native animal receptors expressed
in the periphery and in the CNS.
In the spinal cord, NOP and opioid (particularly the m
opioid receptor) receptor stimulation elicits antinociceptive
effects via similar cellular mechanism, that is presynaptic
inhibition of neurotransmitter release from primary sensory
neurons (Zeilhofer and Calo, 2003). Moreover, recent studies
performed in non-human primates suggest that the simulta-
neous activation of NOP and opioid receptors produces syn-
ergistic antinociceptive effects (Hu et al., 2009; Ko and
Naughton, 2009). This evidence prompted us to assess the
spinal antinociceptive properties of [Dmt1]N/OFQ(1–13)-NH2
in non-human primates. It should be emphasized that in this
species, antinociceptive effects in response to spinal adminis-
tration of NOP agonists are behaviourally selective while
those elicited by m opioid receptor agonists are always associ-
ated with scratching (Ko et al., 2004; 2006). In monkeys,
[Dmt1]N/OFQ(1–13)-NH2 induced significant antinociceptive
effects at the dose of 3 nmol and full antinociception at
10 nmol. Interestingly, over this range of doses, the antinoci-
ceptive effect of [Dmt1]N/OFQ(1–13)-NH2 was not associated
with scratching. Compared with N/OFQ (Ko et al., 2006; Ko
and Naughton, 2009), [Dmt1]N/OFQ(1–13)-NH2 was found to
be about ~10–30-fold more potent and elicited longer-lasting
effects. These results contrast to the similar NOP potency
displayed by [Dmt1]N/OFQ(1–13)-NH2 and N/OFQ or
N/OFQ(1–13)-NH2 in vitro. It has been demonstrated that
[desPhe1]N/OFQ is a major metabolite of N/OFQ when the
peptide is given i.t. (Ko et al., 2006). Therefore, the presence of
the non-natural amino acid Dmt in position 1 may reduce
susceptibility to enzymatic degradation. This may cause an
increase in peptide potency and duration of action in vivo,
where metabolism is likely to be more relevant than in vitro.
However, it is unlikely that the huge increase in [Dmt1]N/
OFQ(1–13)-NH2 potency is solely due to increased metabolic
stability. On the other hand, it is known that m opioid peptide
agonists are very potent analgesics when delivered spinally
(see Malmberg and Yaksh, 1992). However, the analgesic
effects elicited by selective m opioid receptor activation are
always associated with scratching while those elicited with
submaximal doses of [Dmt1]N/OFQ(1–13)-NH2 are not associ-
ated with this unwanted effect. It is therefore suggested that
the high potency of the synthetic peptide mainly derives from
its ability to simultaneously activate spinal NOP and opioid
receptors. This simultaneous receptor activation produced
behaviourally selective synergistic antinociceptive effects as
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demonstrated in previous monkey studies performed with
subthreshold doses of morphine and N/OFQ (Ko and Naugh-
ton, 2009) or the potent and selective NOP agonist UFP-112
(Hu et al., 2009). [Dmt1]N/OFQ(1–13)-NH2 induced scratching
behaviour similar to morphine only at higher supramaximal
doses (i.e. 30 and 100 nmol) (Ko et al., 2006; Ko and Naugh-
ton, 2009). These results further suggest that the high antino-
ciceptive potency of [Dmt1]N/OFQ(1–13)-NH2 may derive
from its mixed NOP/opioid agonist activity. However this is
just a proposal for interpreting our findings, in fact, receptor
antagonist and knockout studies are required to firmly
attribute the in vivo actions of [Dmt1]N/OFQ(1–13)-NH2 to
NOP and/or opioid receptor activation.
I.t infusions of analgesics have been increasingly utilized
during the last two decades for the treatment of persistent
cancer pain. With recent technological advances in the field,
this therapeutic option has been extended to moderate or
severe pain related to cancer and non-cancer origins (Smith
et al., 2008). However, only morphine and ziconotide (Kress
et al., 2009) have been approved for i.t. administration; thus,
there is a strong medical need for novel drugs to be used as
spinal analgesics. In this regard non-selective NOP/opioid
agonists such as [Dmt1]N/OFQ(1–13)-NH2 may represent an
interesting option. Indeed, the synergistic antinociceptive
effect generated by the simultaneous activation of NOP and
MOP receptors may offer important advantages: (i) during
acute administration a complete analgesic effect can be
achieved with fewer or even elimination of the side effects
associated with the full activation of a single receptor; and (ii)
during chronic treatment the desired level of analgesia can
maintained for longer (i.e. reduction in tolerance liability)
because the analgesic action does not derive from the full and
prolonged activation of a single receptor. However, these are
intriguing speculations that need rigorous experimental
validation.
In conclusion, the present study describes the design,
synthesis and in vitro pharmacological characterization
of [Dmt1]N/OFQ(1–13)-NH2, a potent mixed NOP/opioid
agonist. The spinal administration of this peptide in non-
human primates elicits potent antinociceptive effects similar
to those produced by combinations of NOP and opioid
receptor agonists. These results suggest that [Dmt1]N/OFQ(1–
13)-NH2 could be considered the prototype of a novel class
of spinal analgesics worthy of consideration for clinical
development.
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